Upstate Active Clinical Trials

Study Title:

Bayer Protocol Number: 15983- A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients with Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases

What is the purpose of the study?

To evaluate and compare the efficacy and safety of regorafenib versus placebo in subjects with colorectal cancer (CRC) after curative resection of liver metastasis and completion of all planned chemotherapy

Upstate Institutional Review Board (IRB) Number:

555426

Study Phase:

III

Patient Age Group:

Adults

Principal Investigator:

Rahul Seth, DO

ClinicalTrials.Gov ID:

NCT01939223

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Wendy S Barry
Phone: 315-464-8271
Email: barryw@upstate.edu

Return to Previous Page || Search Again